A Case Crossover Study of Intermittent Fasting in CLL/SLL

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

October 30, 2023

Study Completion Date

December 30, 2023

Conditions
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Interventions
BEHAVIORAL

5:2 Method (intermittent fasting regimen)

"Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference."

BEHAVIORAL

16/8 Method (intermittent fast regimen)

Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.

Trial Locations (1)

V8R 6V5

Eleah Stringer, Victoria

All Listed Sponsors
collaborator

BC Cancer Foundation

OTHER

collaborator

University of Victoria

OTHER

lead

British Columbia Cancer Agency

OTHER

NCT05708326 - A Case Crossover Study of Intermittent Fasting in CLL/SLL | Biotech Hunter | Biotech Hunter